CoChat

Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups

Open access
Bolli, Niccolo, Biancon, Giulia, Moarii, Matahi, Gimondi, Silvia, Li, Yilong, de Philippis, Chiara, Maura, Francesco, Sathiaseelan, Vijitha, Tai, Yu-Tzu, Mudie, Laura, O’Meara, Sarah, Raine, Keiran, Teague, Jon W., Butler, Adam P., Carniti, Cristiana, Gerstung, Moritz, Bagratuni, Tina, Kastritis, Efstathios, Dimopoulos, Meletios, Corradini, Paolo, Anderson, Kenneth C., Moreau, Philippe, Minvielle, Stephane, Campbell, Peter J., Papaemmanuil, Elli, Avet-Loiseau, Herve, Munshi, Nikhil C. · 2018 · Leukemia
Cited by 196

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

In multiple myeloma, next-generation sequencing (NGS) has expanded our knowledge of genomic lesions, and highlighted a dynamic and heterogeneous composition of the tumor. Here we used NGS to characterize the genomic landscape of 418 multiple myeloma cases at diagnosis and correlate this with prognosis and classification. Translocations and copy number abnormalities (CNAs) had a preponderant contribution over gene mutations in defining the genotype and prognosis of each case. Known and novel independent prognostic markers were identified in our cohort of proteasome inhibitor and immunomodulatory drug-treated patients with long follow-up, including events with context-specific prognostic value, such as deletions of the PRDM1 gene. Taking advantage of the comprehensive genomic annotation of each case, we used innovative statistical approaches to identify potential novel myeloma subgroups. We observed clusters of patients stratified based on the overall number of mutations and number/type of CNAs, with distinct effects on survival, suggesting that extended genotype of multiple myeloma at diagnosis may lead to improved disease classification and prognostication.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41375-018-0037-9

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 196

Metadata

Authors
Bolli, N., Biancon, G., Moarii, M., Gimondi, S., Li, Y., de Philippis, C., Maura, F., Sathiaseelan, V., Tai, Y.-T., Mudie, L., O’Meara, S., Raine, K., Teague, J. W., Butler, A. P., Carniti, C., Gerstung, M., Bagratuni, T., Kastritis, E., Dimopoulos, M., Corradini, P., Anderson, K. C., Moreau, P., Minvielle, S., Campbell, P. J., Papaemmanuil, E., Avet-Loiseau, H., & Munshi, N. C.
Venue
Leukemia
Published
2018-05-22
Volume
32
Issue
12
Pages
2604-2616
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W2775724281
Cited by
196
References
15
FWCI
14.74
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. https://app.cochat.ai/papers/10.1038/s41375-018-0037-9
The paper
Bolli, N., Biancon, G., Moarii, M., Gimondi, S., Li, Y., de Philippis, C., Maura, F., Sathiaseelan, V., Tai, Y.-T., Mudie, L., O’Meara, S., Raine, K., Teague, J. W., Butler, A. P., Carniti, C., Gerstung, M., Bagratuni, T., Kastritis, E., Dimopoulos, M., . . . Munshi, N. C. (2018). Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. https://doi.org/10.1038/s41375-018-0037-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.